We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Senate Finance Committee and West Virginia’s attorney general are requesting information on the rebates Mylan paid to Medicaid for its allergy treatment EpiPen, a day ahead of a hearing on the price of the combination product. Read More
A federal judge signed off on a $486 million settlement between Pfizer and the company’s shareholders to end a long-standing class action suit alleging the company misrepresented the cardiovascular risks of its analgesics Celebrex and Bextra. Read More
The UK’s price watchdog recommended against expanding reimbursement for Roche’s Esbriet to early treatment of idiopathic pulmonary fibrosis, while still backing the drug for patients with moderate disease progression. Read More
In the EU, biosimilars are poised to join the main market as prescribers widely embrace the lower-cost, copycat versions of the brand-name drugs. Read More
Almost a year after Bayer settled pay-for-delay allegations involving its antibiotic Cipro, Ireland-based Allergan and France-based Sanofi units have struck deals to resolve lingering Cipro claims in ongoing class action litigation, agreeing to pony up $100 million. Read More
New Mexico Attorney General Hector Balderas has filed a lawsuit against Bristol-Meyers Squibb, alleging the company engaged in false and deceptive marketing of its blood thinner Plavix. Read More